MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats

A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

Meeting: 2017 International Congress

Abstract Number: 908

Keywords: Neuroprotective agents

Session Information

Date: Wednesday, June 7, 2017

Session Title: Neuropharmacology

Session Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Objective: This study examined the effect of pretreatment with Myristicin on the severity of 6-hydroxydopamine-induced Parkinsonism in Wistar rats in order to find out whether Myristicin could attenuate oxidative stress markers, behavioral and structural abnormalities in an experimental model of PD in rat.

Background: Parkinson’s disease refers to a progressive neurodegenerative disorder involving degeneration of dopaminergic neurons particularly in substantia nigra. The loss of dopaminergic cells results in complex motor syndrome. One of the hypothesis in pathogenesis of PD is oxidative stress via NADPH-dependent oxidases. Myristicin have been reported to increase oxidative burden.

Methods: 72 male wistar rats were divided into six groups: (1) sham, normal saline was injected in the left SNC (substantia nigra pars compacta) , (2) 6-OHDA, 6-hydroxydopamine was injected into left SNC, (3) 6-OHDA+Captopril (5 mg/kg, i.p), (4) 6-OHDA+Myristicin (5 mg/kg, i.p), (5) 6-OHDA+Myristicin (20 mg/kg, i.p), (6) 6-OHDA+Myristicin (100 mg/kg, i.p). Myristicin and captopril were injected rats daily from six dayes before the surgery to a day after. At the end of the experiment brain’s oxidative stress markers; Lipid peroxidation and protein oxidation, apomorphine-induced rotational asymmetry were measured and the number of Nissl-stained neurons in SNC after 2 weeks were counted.

Results: Myristicin administration could attenuate the rotational behavior (p﹤0,05). and Myristicin also decrease the amounts of oxidative stress markers in lesioned rats and protect the neurons of SNC against 6-OHDA toxicity in comparison with the group which received only neurotoxin (p﹤0,01).

Conclusions: In conclusion, the results of the present study suggest that Myristicin administration has a protective effect against 6-OHDA toxicity and may be useful for treatment of parkinson’s disease.

References: Moradganjeh, A. 2013. Losartan pretreatment reduces neurodegeneration … – Pathophysiology. http://www.pathophysiologyjournal.com/article/S0928-4680(13)00055-2/abstract. Zhang, H. 2006. Evaluation of antioxidant activity of parsley (Petroselinum crispum … http://www.xoc.uam.mx/files/4958/application/pdf/Evaluation-of-antioxidant-activity-of-parsley-(Petroselinum-crispum)-essential-oil.pdf.

To cite this abstract in AMA style:

A. Morad Ganjeh. Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/protective-effect-of-myristicin-against-neurodegeneration-in-a-6-hydroxydopamine-induced-model-of-parkinsons-disease-in-rats/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/protective-effect-of-myristicin-against-neurodegeneration-in-a-6-hydroxydopamine-induced-model-of-parkinsons-disease-in-rats/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley